Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Схожие документы

• The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas
  по: Anderson, Ryan T., et al.
  Опубликовано: (2013)
• Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas
  по: Hernandez, Ariel L., et al.
  Опубликовано: (2019)
• Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors
  по: Jimeno, Antonio, et al.
  Опубликовано: (2008)
• Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies
  по: Roschewski, Mark, et al.
  Опубликовано: (2013)
• Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib(®)), a phase III clinical stage anti-cancer agent()
  по: Pallela, Venkat R., et al.
  Опубликовано: (2013)